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 Chapter 1   General Introduction 
 
1. Background 
1.1 Cancer 
The systematic translation of fundamental cancer research data into knowledge of tumor biology and 
therapeutic possibilities still remains challenging. Such efforts should be greatly aided by robust preclinical 
investigation systems that reflect the intrinsic property of cancer and for which detailed molecular 
mechanisms and pharmacological annotations are available. Cancer also links to the other diseases. For 
example, senescence-associated secretory phenotype has crucial roles in promoting obesity-associated 
 
Figure 1-1 The Hallmarks of Cancer. The past decade has witnessed remarkable progress toward 
understanding the mechanistic underpinnings of each hallmark. (Hanahan, D. & Weinberg, R. A., Cell, 
2011) 
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 hepatocellular carcinoma development, providing valuable new insights into the development of obesity-
associated cancer.1 The six hallmarks of cancer—distinctive and complementary capabilities that enable 
tumor growth and metastatic dissemination—continue to provide a solid foundation for understanding 
carcinogenesis (Figure 1-1).2 The intracellular integrated circuits can be segmented into distinct subcircuits, 
each of which is specialized to support a discrete cell-biological property in normal cells and is 
 
Figure 1-2 Intracellular signaling networks regulate the operations of the cancer cell. An elaborate 
integrated circuit operates within normal cells and is reprogrammed to regulate hallmark capabilities within 
cancer cells. Separate subcircuits, depicted here in differently colored fields, are specialized to orchestrate 
the various capabilities. At one level, this depiction is simplistic, as there is considerable crosstalk between 
such subcircuits. (Modified from Hanahan, D. & Weinberg, R. A., Cell, 2011) 
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 reprogrammed in order to implement the hallmarks in cancer cells (Figure 1-2).2 Importantly, changes in 
gene expression play central roles in these networks formed by various of distinct circuits and contribute to 
cancer hallmarks. Comprehensive knowledge of the genes underlying cancer is a critical foundation for 
cancer therapy. Now the major international projects are underway aimed at creating a comprehensive 
catalogue of all the genes responsible for the initiation and progression of cancer.3 Previous cancer studies 
have led to the identification of scores of cancer-associated genes, including both tumor suppressor genes 
and oncogenes. Substantially, large-scale analysis of the cancer genome has provided an unprecedentedly 
detailed picture of cancer, which has been, and continues to serve as, a blueprint for the development of 
molecular-targeted therapies.4 
Tumor suppressor genes encode a broad class of molecules whose downregulation (lost or markedly 
reduced or mutational attenuation) contributes to malignant progression. As a well-known instance, a mouse 
model demonstrated that deleted in colorectal carcinoma (DCC) functions as a tumor suppressor via its 
ability to trigger tumor cell apoptosis5 and limits survival of disseminated tumor cells6. In addition, the 
well-established p53 tumor suppressor has been attractive during the past decades. The latest report found 
that transient p53-p21 activation and cell-cycle arrest promoted cell survival by efficiently channeling 
depleted serine stores to glutathione synthesis, thus preserving cellular anti-oxidant capacity. Cells lacking 
p53 failed to complete the response to serine depletion, resulting in oxidative stress, reduced viability and 
severely impaired proliferation, indicating that serine depletion has a potential role in the treatment of p53-
deficient tumors.7  
Targeted therapies directed against amplified or mutant-activated key driver oncoproteins have 
demonstrated efficacy against specific subsets of molecularly defined cancers and provided encouraging 
clinical implications. Oncoprotein triggers the activation of oncogenetic signaling pathways, such as mTOR 
signalling8 and AMP-activated protein kinase (AMPK) pathways9, during carcinogenesis and metastasis. 
For instance, as a typical oncoprotein, COUP transcription factor II (COUP-TFII), a member of the nuclear 
receptor superfamily, serves as a key regulator to inhibit SMAD4-dependent transcription, and 
consequently overrides the TGFβ-dependent checkpoint for PTEN-null indolent tumors (Figure 1-3).10 
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 Some oncogenes even exert the tumor-promoting effects by their RNA format after transcription. An 
outstanding study demonstrated that HMGA2 (a well-known oncoprorein) mRNA promotes lung cancer 
progression by operating as a competing endogenous RNA (ceRNA) for the let-7 microRNA (miRNA) 
family. HMGA2 can promote the transformation of lung cancer cells independent of protein-coding 
function but dependent upon the presence of let-7 sites; mechanistically, TGFBR3 serves as a putative 
target of HMGA2 ceRNA function.11 These findings highlight the vital roles of oncogenes in their functions 
as ceRNAs and emphasize the ceRNAs as novel pools of therapeutic targets.  
 
Figure 1-3 Model of COUP-TFII in prostate tumorigenesis. PTEN inactivation drives prostate tumor 
initiation and progression. However, it also elicits the activation of TGFβ signalling that induces cellular 
senescence to constrain the indolent tumor from becoming aggressive. To develop metastasis-prone tumors, 
alternative oncogenic signals stimulate COUP-TFII expression, which counteracts the TGFβ-dependent 
checkpoint through direct association with SMAD4. Thus, COUP-TFII serves as a crucial regulator that 
counteracts the TGFβ-dependent growth barrier to enable indolent prostate cancer tumors to acquire 
metastatic potential. (Qin, J. et al. Nature, 2013) 
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 1.2 Aging-associated gene 8 (AAG8) 
 
AAG8, encoded by the SIGMAR1 gene, was originally considered an enigmatic polypeptide and has 
recently been identified as a unique ligand-regulated chaperone protein. AAG8 is widely expressed with 
higher expression in liver, colon, prostate, placenta, small intestine, heart and pancreas (Figure 1-4, 1-5). It 
is also expressed in the retina by retinal pigment epithelial cells (Figure 1-5). 
 
 
Figure 1-4 AAG8 expression pattern in normal and cancer cells. (Data from Genecard databases. 1: 
MOPED database; 2: PaxDb database; 3: MAXQB database. http://www.genecards.org/cgi-
bin/carddisp.pl?gene=SIGMAR1) 
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Figure 1-5 AAG8 expression in normal human tissues 
(normalized intensities, Data from Genecard 
databases) 
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 The chaperone domain of AAG8 is C-terminal to two putative transmembrane domains (residues 11-29 
and 80-100) but contains a predicted membrane associated region (residues ~176-204) containing two 
cholesterol recognition motifs (CRM) (Figure 1-6). Solution NMR spectroscopy studies found that the 
chaperone domain contains a helix at the N terminus followed by a largely dynamic region and a structured, 
helical C-terminal region that encompasses a membrane associated domain containing four helices. The 
helical region at residues ~198-206 is amphipathic and proposed to anchor the chaperone domain to 
micelles and membranes. Three of the helices in the C-terminal region closely correspond to cholesterol 
and drug recognition sites. In addition, the chaperone domain interacts with HSP70 binding 
immunoglobulin protein (BiP) and regulates the inositol triphosphate receptor calcium channel.12 AAG8 
may exist naturally in equilibrium among monomeric, dimeric, and/or oligomeric forms according to an 
AAG8 ligand-based structural prediction study (Figure 1-7).13 
 
 
Figure 1-6 Full-length AAG8 topology schematic showing two predicted transmembrane helices (TM1 and 
TM2) and the membrane-associated domain. The N and C termini and the approximate positions of residues 
112 and 223 (the C-terminal residue) are indicated. TM1, transmembrane domain 1; TM2, transmembrane 
domain 2; Cyt., cytosol. (Ortega-Roldan, J. L., et al. J Biol Chem, 2013) 
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Figure 1-7 Models of the AAG8 (S1R) ligand binding region. (A) Model of the sigma-1 receptor binding 
region from previous photolabeling studies and from the results with the derivatization by its ligand 4-
NPPC12. D188, aspartate 188; H154, histidine 154. The shaded area represents the ligand binding region. 
(B) Proposed model of AAG8 in the presence of 4-NPPC12. (Chu, U. B, et al. Biochemistry-Us, 2013) 
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 AAG8 is predominantly expressed at the mitochondria-associated endoplasmic reticulum (ER) 
membrane (MAM) and distributes dynamically (Figure 1-8). The MAM, highly capable of accumulating 
ceramides, is a small section of the outer mitochondrial membrane tethered to the ER by lipid and protein 
filaments and is enriched with both cholesterol and simple sphingolipids. A lipid overlay assay found that 
AAG8 preferentially associates with simple sphingolipids such as ceramides. AAG8 associates with MAM-
derived detergent-resistant membranes (DRMs) which play an important role in anchoring AAG8 to the 
MAM. Disrupting DRMs by lowering cholesterol or inhibiting de novo synthesis of ceramides at the ER 
largely decreases AAG8 at DRMs and causes translocation of AAG8 from the MAM to ER cisternae, 
suggesting that the MAM, bearing cholesterol and ceramide-enriched microdomains at the ER, may use the 
microdomains to anchor AAG8 to the location; thus, it serves to stage AAG8 at ER-mitochondria 
junctions.14  
 
Figure 1-8 Proposed model of interaction between ER and mitochondria through the MAM resident AAG8 
(Sigma-1). (Hayashi, T. et al. Mol Pharmacol, 2010) 
 
Due to its localization, AAG8 modulates both MAM-specific and plasma membrane proteins and 
mitochondrial metabolisms. AAG8 at the MAM coordinates with steroidogenic acute regulatory protein for 
cholesterol trafficking into the mitochondria for metabolic regulation.15 Furthermore, AAG8 promotes 
degradation of UDP-galactose:ceramide galactosyltransferase (CGalT), a glycoprotein that synthesizes 
galactosylceramides at ER, by forming a complex with Insig (Figure 1-9), suggesting that AAG8 is involved  
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Figure 1-9 A scheme depicting a putative molecular action of AAG8 (Sig-1R) regulating the CGalT level. 
The second transmembrane domain of the AAG8 associates with Insig to form an ERAD complex at the 
ER membrane. In the presence of high sterols (e.g. 25-hydroxysterol), CGalT is recruited to the AAG8-
Insig machinery for degradation. Other components involved in the AAG8-regulated ERAD machinery 
(e.g. ubiquitin ligases) are not defined. The transmembrane domain of CGalT (a gray box) contains a 
putative sterol-binding motif that, upon binding to sterols, might be recognized by the Insig-mediated 
ERAD complex. (Hayashi, T. et al. J Biol Chem, 2012) 
 
in post-translationally regulation and ER-associated degradation.16 Importantly, AAG8 chaperones the ER 
stress sensor inositol-requiring protein 1 (IRE1), which is enriched at the MAM, to facilitate inter-organelle 
signaling for survival. IRE1 is stabilized at the MAM by AAG8 when cells are under ER stress. AAG8 
stabilize IRE1 and thus allow for conformationally correct IRE1 to dimerize into the long-lasting, activated 
endonuclease (Figure 1-10). The IRE1 at the MAM also responds to reactive oxygen species derived from 
mitochondria. Therefore, the ER-mitochondrion interface serves as an important subcellular entity in the 
regulation of cellular survival by enhancing the stress-responding signalling between mitochondria, ER, 
and nucleus.17 
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Figure 1-10. Schematic model depicting the role of AAG8 (Sig-1R) in the activation of IRE1. AAG8 
enhances its association with IRE1 to correct or stabilize the conformation of IRE1 when cells are facing 
ER stress (i.e., as indicated in the blue-lined rectangle). This transient association of the AAG8 with IRE1 
interferes with the dimerization of IRE1, leading to a delay in the transautophosphorylation of IRE1. This 
delayed dimerization/phosphorylation, however, ensures a long-lasting active form of IRE1 (the 
cytoplasmic domain filled in red) which splices the XBP1 mRNA. In lower panels, when AAG8 knockdown 
cells encounter ER stress, IRE1, although being misfolded, can still quickly dimerize and 
transautophosphorylate. The conformationally awry pIRE1, which may still possess endonuclease activity 
albeit being less compared to controls, is however readily ubiquitinated and degraded by proteasomes. 
(Mori, T. et al. Plos one, 2013) 
 
 
11 
 
 AAG8 has been intensively elaborated in neuroscience and mutations of AAG8 have been shown to cause 
neurodegenerative diseases such as amyotrophic lateral sclerosis.18-32 AAG8 is an interorganelle signaling 
modulator that potentially plays a role in drug-seeking behaviors. Spinal AAG8-induced sensitization is 
mediated by an increase in nNOS activity, which is associated with an NO-induced increase in PKC-
dependent pGluN1 expression (Figure 1-11).33 In the brain, it interacts functionally with a variety of ion 
channels and regulates their activities. Cocaine exposure can trigger an AAG8-dependent upregulation of 
D-type K+ current in the nucleus accumbens that results in neuronal hypoactivity and thereby enhances 
behavioral cocaine response. Combined ex vivo and in vitro studies demonstrated that this neuroadaptation 
is caused by a persistent protein-protein association between AAG8 and Kv1.2 channels, a phenomenon 
that is associated to a redistribution of both proteins from intracellular compartments to the plasma 
membrane. In conclusion, the dynamic AAG8-Kv1.2 complex represents a mechanism that shapes neuronal 
and behavioral response to cocaine. Functional consequences of AAG8 binding to K+ channels may have 
implications for other chronic diseases where maladaptive intrinsic plasticity and AAG8 are engaged 
(Figure 1-12).34 In addition to Kv1.2 channels, AAG also binds to the Nav1.5 Na+ channels. Atomic force 
microscopy imaging of complexes between AAG8 and Nav1.5 Na+ channels reveals a 4-fold symmetry, 
i.e., each of the four sets of six transmembrane regions in Nav1.5 constitutes an AAG8 binding site. As a 
result, AAG8 knockdown strongly reduces the voltage-dependent Na+ current (Figure 1-13).35 Besides ion 
channels, a study using atomic force microscopy (AFM) imaging found that AAG8 bound directly to 
GluN1/GluN2A NMDA receptor (NMDAR) heterotetramers. In situ proximity ligation assays 
demonstrated that the Sig1R interacts with GluN1 within intact cells and also that its C terminus is 
extracellular (Figure 1-14). Therefore AAG8 binds to the GluN1/GluN2A NMDAR specifically via the 
GluN1 subunit.36 This interaction likely accounts for at least some of the modulatory effects of Sig1R 
ligands on the NMDAR. 
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Figure 1-11 Schematic diagram that summarizes the proposed mechanism for how activation of AAG8 
(Sig-1R) in turn activates nitric oxide (NO), which then stimulates pGluN1(NMDA R) via a protein kinase 
C (PKC) mechanism to ultimately facilitate pain. AAG8 activation stimulates PLC to hydrolyze PIP2 to 
produce diacyl glycerol (DAG) and IP3. IP3 then binds to IP3 receptors (IP3-R) in the endoplasmic 
reticulum to promote the efflux of Ca2+ to the cytoplasm. Increased cytosolic Ca2+ then influences 
calcineurin activity and via this mechanism reduces the phosphorylation of nNOS (i.e. resulting in an 
increase in nNOS activity). The NO generated from nNOS stimulates cGMP production via sGC, which in 
turn leads to an increase in PKC activity. The increase in cGMP is likely to produce the PKC activation, 
which induces the phosphorylation of the PKC-dependent NMDA receptor GluN1 subunit, resulting in the 
initiation of the pain facilitatory effect. In addition, the diffusible NO produced AAG8 activation can also 
contribute to the pain facilitatory effect by diffusion from the cell to affect other cells. AAG8 activation 
leads to an increase in activated nNOS, which plays a key role in AAG8-mediated mechanical and thermal 
hypersensitivity and PKC-dependent, but not PKA-dependent, pGluN1 expression. (Roh, D. H. et al. Brit 
J Pharmacol, 2013) 
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Figure 1-12 Dynamic interaction between AAG8 (Sig-1R) and Kv1.2 shapes neuronal and behavioral 
responses to cocaine. (Kourrich, S. et al. Cell, 2013) 
 
 
 
Figure 1-13 AAG8 regulates Nav1.5 current density inMDA-MB-231 cells. Figure shows the representative 
Na+ currents elicited in Sig1R knockdown or control MDA-MB-231 cells. (Balasuriya, D. et al. J Biol 
Chem, 2012) 
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Figure 1-14 Schematic illustration of the in situ proximity ligation assay for AAG8 (Sig1R) plus GluN1. 
PM, plasma membrane. (Balasuriya, D. et al. J Neurosci, 2013) 
 
A plethora of ligands of AAG8 has been synthesized.37,38 A methodology for monitoring AAG8 activation 
switch in living cells was developed recently (Figure 1-15). This biosensor uncovered the intrinsic nature 
of AAG8 ligands by recording the ligand-mediated conformational changes. The change triggered by each 
ligand correlated well with its ability to attenuate formalin induced nociception in an animal model of 
pain.39 With the use of these ligands, functions of AAG8 in the central nervous system (CNS) have been 
evaluated. Importantly, AAG8 was found to mediate pain hypersensitivity in mice and neuropathic pain in 
rats. Direct activation of the spinal AAG8 with PRE084, a specific AAG8 agonist, produces mechanical 
allodynia and induced an increase in NOX2 activation and reactive oxygen species (ROS) production in  
 
Figure 1-15 Predicting the antinociceptive efficacy of AAG8 (σ1R) ligands by a receptor FRET-based 
biosensor. (Gomez-Soler, M. et al. J Med Chem, 2014) 
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 mice, which can be attenuated by pretreatment with the selective AAG8 antagonist, BD1047. This 
demonstrates that spinal AAG8 modulate NOX2 activation and ROS production in the spinal cord, and 
ultimately contribute to the AAG8-induced pain hypersensitivity and the peripheral nerve injury-induced 
induction of chronic neuropathic pain (Figure 1-16).40 On the other hand, intrathecal injection of PRE084 
into naïve mice time-dependently increases the expression of p-p38, which can be blocked by pretreatment 
with BD1047. Intrathecal pretreatment with SB203580, a p38 inhibitor also dose-dependently inhibited 
PRE084-induced mechanical allodynia, demonstrating that the increase in spinal p-p38 is closely associated 
with the induction of AAG8 mediated mechanical allodynia.41 AAG8 stimulation with its specific agonist 
SA4503 ameliorates cardiac hypertrophy and dysfunction by restoring both mitochondrial Ca2+ 
mobilization and ATP production, suggesting that AAG8 stimulation represents a strategy to rescue the 
heart from hypertrophic dysfunction (Figure 1-17).42 A research group recently argued that treatment with 
some AAG8 ligands induces ER stress and activates the unfolded protein response (UPR). Autophagy is 
engaged after extended treatment with AAG8 ligands, which suggests that protracted  
 
Figure 1-16 Spinal AAG8 (Sig-1R) activate NADPH oxidase 2 leading to the induction of pain 
hypersensitivity in mice and mechanical allodynia in neuropathic rats. (Choi, S. R. et al. Pharmacol Res, 
2013) 
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 UPR results in autophagy as a secondary response. In addition, UPR activation precedes autophagosome 
formation and autophagy precedes apoptosis in AAG8 ligand-treated cells, suggesting that UPR and 
autophagy are engaged as primary and secondary cytoprotective responses, respectively, to AAG8 ligand-
induced disruption of cell protein homeostasis.43 
 
 
Figure 1-17 Shown is a model of regulation of Ca2+ homeostasis and ATP production by SA4503 through 
AAG8 (σ1R) stimulation. AAG8 stimulation with SA4503 promotes mitochondrial Ca2+ influx and 
mitochondrial Ca2+-dependent ATP production. AAG8-induced regulation of Ca2+ homeostasis and ATP 
production is crucial for the cardioprotective activity of SA4503 against heart failure. VDAC: voltage-
dependent anion channel. (Tagashira, H. et al. Bba-Gen Subjects, 2013) 
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 2. Objective 
 
Despite the notable advantages described above, people have only just begun to define the underlying 
mechanisms of AAG8, even in the field of neurology. Although recent emerging in vitro and in vivo 
evidences have implied AAG8 as a pharmacological target for the treatment of neurological disorders, little 
has been investigated regarding the roles of AAG8 in cancinogenesis. In contrast to the intensive use of 
AAG8 ligand for investigation of AAG8 in neurology, few ligands have been tested for their anti-cancer 
property. Growth-inhibitory effects of the novel selective AAG8 antagonists in a breast cancer cell line has 
been solely reported, however, molecular explanation was absent.44 More importantly, since drug resistance 
and great side effects has largely impeded the efficient curable therapy for cancer, especially for MAPK-
hyperactivated melanoma, it is necessary to discover the novel and potential inhibitors that target the 
important oncogenetic signalling cascades. 
Despite the previously described findings of AAG8 in neuroscience, the importance of AAG8 in cancer 
has rarely been noticed, and the lack of gain- or loss-of-function studies has so far precluded a clear 
understanding of the rationale of AAG8 in carcinogenesis. This study therefore focuses on the molecular 
mechanisms of AAG8 and its ligands especially the antagonists and aims at characterization of its intrinsic 
functions in cancer. 
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 3. Dissertation composition  
 
This dissertation is composed of five chapters. In Chapter 1, general introduction including background 
(cancer and AAG8) and objective of this dissertation is described. In Chapter 2, I investigated the effects 
and mechanisms of AAG8 antagonism in melanoma cells, and proposed a novel strategy for melanoma 
therapy through tandem AAG8-MEK inhibition. Though this study, AAG8 antagonists have been 
discovered as novel MEK inhibitors. Finally, based on the experimental data, critical discussions are made 
regarding the several important arguable topics. In Chapter 3, I explored the intrinsic roles of AAG8 in 
cancer cells and found that AAG8 promoted carcinogenesis both in vitro and in vivo. I further characterized 
AAG8, for the first time to our knowledge, as a STAT3 activator, and demonstrated that it alternatively 
activated STAT3 in addition to IL6/JAK pathway. Finally, based on the experimental data, critical 
discussions are made regarding the several important arguable topics. In the last chapter, final conclusion 
is obtained and future perspective is proposed.  
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 4. Abbreviation 
 
AAG8  Aging-associated gene 8 
MAPK  Mitogen-activated protein kinase 
STAT3  Signal transducer and activator of transcription 3 
API4  Apoptosis inhibitor 4 
ER  Endoplasmic reticulum 
MAM  Mitochondria-associated endoplasmic reticulum membrane 
JAK  Janus kinases 
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 Chapter 2  Modeling Tandem AAG8-MEK Inhibition in Melanoma Cells 
 
1 Introduction 
1.1 MEK signalling 
 
The cellular kinase-signalling network is a major regulator in pathogenesis, and kinase mutations are 
common and potent drivers of oncogenesis. The mitogen-activated protein kinase (MAPK), i.e. RAS-RAF-
MEK-ERK signaling pathway, is a key modulator of cellular proliferation, differentiation and survival 
downstream of RAS activation. Upregulation of this pathway occurs in a large fraction of tumors, frequently 
owing to oncogenic activating mutations in KRAS, NRAS, HRAS and BRAF.45 Somatic mutations in the 
small GTPase RAS family proteins are the most common activating lesions found in cancer, and are 
generally associated with poor response to standard therapies. Oncogenic mutations result in functional 
activation of RAS by impairing GTP hydrolysis. With diminished regulation by GTPase activity, the 
nucleotide state of RAS becomes more dependent on relative nucleotide affinity and concentration. This 
gives GTP an advantage over GDP and increases the proportion of active GTP-bound RAS.  
 
 
Figure 2-1 Model depicting the KRAS-regulated Glutamine metabolic reprogramming used to maintain 
redox and support growth. (Son, J. et al. Nature, 2013) 
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 The Cancer Cell Line Encyclopedia (CCLE), a compilation of gene expression, chromosomal copy 
number and massively parallel sequencing data from 947 human cancer cell lines, enabled identification of 
genetic, lineage, and gene-expression-based predictors of drug sensitivity. Within CCLE, AHR gene (which 
encodes the aryl hydrocarbon receptor) expression was found to be associated with MEK inhibitor efficacy 
in NRAS-mutant lines.46 Sleeping Beauty transposon-mediated insertional mutagenesis studies in a mouse 
model of pancreatic ductal preneoplasia identified genes, especially the X-linked deubiquitinase USP9X, 
that cooperate with oncogenic KRAS-G12D to accelerate tumorigenesis and promote progression.47 In 
pancreatic ductal adenocarcinoma cells, a non-canonical pathway of glutamine use was identified to be 
required for tumor growth, and this reprogramming of glutamine metabolism is mediated by oncogenic 
KRAS (Figure 2-1).48 Targeting a single kinase has proven successful in some cases. Ostrem, J. M. et al. 
reported the development of small molecules that irreversibly bind to a common oncogenic mutant, KRAS-
G12C and decreased its association with BRAF and CRAF.49 Interfering with binding of mammalian PDEδ 
to KRAS by means of small molecules provides a novel opportunity to suppress oncogenic RAS signalling 
by altering its localization to endomembranes (Figure 2-2).50  
 
 
Figure 2-2 Structure of a small molecule (orange sticks) in complex with PDEδ. (Zaidi, M. R. et al. Nature, 
2011) 
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 1.2 Melanoma 
 
Melanoma is a lethal cancer notable for its aggressive, metastatic and chemoresistant propensity. The 
known environmental and genetic risk factors include ultraviolet radiation exposure51, pigmentation and 
nevus phenotypes.52 Intermittent intense ultraviolet (UV) exposure represents an important aetiological 
factor in the development of malignant melanoma. The ability of UV radiation to cause tumour-initiating 
DNA mutations in melanocytes is now firmly established. Repetitive UV exposure of primary cutaneous 
melanomas in a genetically engineered mouse model promotes metastatic progression, independent of its 
tumour-initiating effects. UV irradiation enhanced the expansion of tumor cells along abluminal blood 
vessel surfaces and increased the number of lung metastases. The UV-induced neutrophilic inflammatory 
response stimulated angiogenesis and promoted the ability of melanoma cells to migrate towards 
endothelial cells and use selective motility cues on their surfaces. UV irradiation of epidermal keratinocytes 
is sensed by the innate immune system, but also show that the resulting inflammatory response catalyses 
reciprocal melanoma-endothelial cell interactions leading to perivascular invasion, a phenomenon 
originally described as angiotropism in human melanomas by histopathologists. Angiotropism represents a 
hitherto underappreciated mechanism of metastasis that also increases the likelihood of intravasation and 
haematogenous dissemination. Ulcerated primary human melanomas with abundant neutrophils and 
reactive angiogenesis frequently show angiotropism and a high risk for metastases.53  
Recent efforts employing whole-genome sequencing or chemical genetic screen methods have identified 
a panel of candidate molecules, including both recurrently mutated or wild-type proteins54,55 and RNAs56,57, 
which contribute to melanomagenesis. Nevertheless, more than half of melanomas express the mutationally 
activated BRAF (V600E, the most prevalent genetic alteration) oncoprotein, which triggers the BRAF-
MEK-ERK signaling pathway (MAPK pathway), a key regulator of proliferation and differentiation. 
Consequently, inhibitors targeting the clinically validated class of molecular components of MAPK cascade 
have been developed and shown to have notable clinical effects for melanoma chemotherapy. RNAi-based 
genetic screen was performed to search for kinases whose knockdown synergizes with BRAF (V600E) 
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 inhibition. With this method, it was found that blockade of the epidermal growth factor receptor (EGFR) 
shows strong synergy with BRAF (V600E) inhibition. Mechanistically, BRAF (V600E) inhibition causes 
a rapid feedback activation of EGFR, which supports continued proliferation in the presence of BRAF 
(V600E) inhibition. Our data suggest that BRAF (V600E) mutant colon cancers, for which there are 
currently no targeted treatment options available, might benefit from combination therapy consisting of 
BRAF and EGFR inhibitors.58 
For instance, Das Thakur and colleagues argued that vemurafenib-resistant melanoma cells exhibit 
similar resistance to the MEK inhibitor AZD6244, due to elevated BRAF (V600E) expression.59 In addition, 
melanoma even elicits resistance to adoptive T-cell transfer therapies through the proinflammatory cytokine 
tumor necrosis factor (TNF)-induced reversible dedifferentiation, hinting strategies to sustain T-cell 
effector functions through minimizing immune-inhibitory effects in the melanoma microenvironment.60 
These studies present an embarrassed situation in dealing with the drug resistance of melanoma. 
A recent study pinpointed a critical role of pyruvate dehydrogenase (PDH) in BRAF (V600E)-driven 
senescence of melanoma, showing that BRAF (V600E)-induced senescence was accompanied by 
simultaneous suppression of the PDH-inhibitory enzyme pyruvate dehydrogenase kinase 1 (PDK1) and 
induction of the PDH-activating enzyme pyruvate dehydrogenase phosphatase 2 (PDP2).61 
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 1.3 Drug resistance 
 
Efforts of cancer drug development have been mixed. Difficulties include rapidly emerging resistance as 
well as considerable toxicity that can limit dosing to levels that are insufficient for blocking tumor growth.62 
Clinical responses to anticancer therapies are often restricted to a subset of patients.63 Cancers acquire 
resistance to systemic treatment as a result of clonal evolution and selection.64 Drug resistance frequently 
results in relapse and presents a challenge for curable therapy. Proteomic analysis showed that stromal cell 
secretion of hepatocyte growth factor (HGF) resulted in activation of the HGF receptor MET, reactivation 
of the MAPK and phosphatidylinositol-3-OH kinase (PI3K)-AKT signalling pathways, and immediate 
resistance to RAF inhibitors.3,65 
Genetically engineered mouse models have been used for conducting a ‘co-clinical’ trial that mirrors an 
ongoing human clinical trial in patients with KRAS-mutant lung cancers. This trial aimed to determine if 
the MEK inhibitor selumetinib (AZD6244) increases the efficacy of docetaxel, a standard of care 
chemotherapy. Concomitant loss of either p53 or LKB1 (also known as STK11), two clinically relevant 
tumour suppressors, markedly impaired the response of KRAS-mutant cancers to docetaxel monotherapy. 
Addition of selumetinib provided substantial benefit for mice with lung cancer caused by KRAS and KRAS 
and p53 mutations, but mice with KRAS and LKB1 mutations had primary resistance to this combination 
therapy.66 To uncover biomarkers of sensitivity and resistance to cancer therapeutics, a panel of several 
hundred cancer cell lines, which represent much of the tissue-type and genetic diversity of human cancers, 
was screened with 130 drugs under clinical and preclinical investigation. In aggregate, mutated cancer 
genes were associated with cellular response to most currently available cancer drugs. Classic oncogene 
addiction paradigms were modified by additional tissue-specific or expression biomarkers, and some 
frequently mutated genes were associated with sensitivity to a broad range of therapeutic agents. By linking 
drug activity to the functional complexity of cancer genomes, systematic pharmacogenomic profiling in 
cancer cell lines provides a powerful biomarker discovery platform to guide rational cancer therapeutic 
strategies.63 
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 1.4 Objective 
 
Although converging in vivo evidences have advanced AAG8 as a pharmacological target for the treatment 
of neurological disorders, little has been investigated in detail about the roles of AAG8 in cancer. In contrast 
to the intensive investigation of AAG8 in neurology, few ligands have been tested for their anti-cancer 
property. Growth-inhibitory effects of the novel selective AAG8 antagonists in a breast cancer cell line has 
been documented, however, molecular explanation was lacking.44 In this chapter, I discovered AAG8 
antagonists as novel MEK inhibitors in melanoma cells and demonstrated the molecular mechanisms that: 
1. AAG8 antagonism restricts melanoma cell growth by inactivation of the CARF-MEK signalling pathway; 
2. AAG8 antagonist resistant melanoma cells obtain refractory CARF-MEK activity, which was not due to 
RAS activation. Finally, tandem AAG8 and MEK inhibition cooperatively and more efficiently kill the 
drug resistant melanoma cells. 
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 2. Material and Methods 
 
2.1 Cell line and reagents: 
 
B16 cells were obtained from ATCC (CRL-6323) and were routinely cultured in Dulbecco’s Modified 
Eagle’s Medium (DMEM) (Nissui Pharmaceutical, Japan) supplemented with 10% fetal bovine serum 
(FBS, GIBCO 10099) and glutamine (SIGMA, G8540) (hereafter complete DMEM). Cell culture was 
maintained in a standard incubator at 37°C with 5% CO2. B16 cells were seeded at a density of 5 × 105 per 
well in 6-well plates for BD1047, BD1063 (SANTA CRUZ, USA), and PD901 (WAKO, Japan) treatment. 
MatrigelTM basement membrane matrix was from BD Bioscience. 
 
2.2 3D culture.  
 
3D on-top culture of melanoma cells was as described previously with some modifications.67 Briefly, 
surface of 6-well plates was coated with pre-thawed Matrigel (500 μl/well) with a pipette tip. For each well, 
105 cells were resuspended in 3 ml of complete DMEM containing 5% Matrigel and pipetted onto the pre-
coated surface. AAG8 antagonists were added into the medium as indicated. Cells were then cultured for 
the indicated days before further assays. 
 
2.3 Wound healing assay 
 
Wound healing assay was performed as described elsewhere.68 Briefly, cells were seeded at low confluency 
(15%) in 6-cm dishes in complete DMEM. Confluent cells monolayer was scraped with a P200 tip to obtain 
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 a wound in each dish, and the medium was replaced with fresh serum-free medium. After 20 hr the cells 
were fixed with 4% paraformaldehyde and photographed. Pictures were taken at time 0 as reference. 
 
2.4 SDS-PAGE and Western blot 
 
Cells were plated 1 day before drug treatment in a 6-well plate at 5 × 105 cells per well for 2D culture, and 
were treated the next day. At the designated time points, cells were lysed with Laemmli buffer. Cytoplasmic 
and nuclear fractions were prepared with NE-PER Nuclear and Cytoplasmic Extraction Reagents (Thermo 
Scientific, USA) according to the manufacturer’s instructions. RAS activity was examined with a RAS 
Activation Assay Kit (Millipore, Germany) as its manual instructed. Each lysate sample was loaded into 
two adjacent lanes of a 10% polyacrylamide gel for minimizing loading differences if indicated. Proteins 
were separated at 30 mA and transferred onto PVDF membranes (Millipore) using the Trans-Blot SD Semi-
Dry Transfer Cell (BIORAD, USA). Membranes were blocked for 1 hr at room temperature using 5% skim 
milk or 5% BSA (for phosphorylation detection) in TBS-Tween (TBS-T). Western blot analysis was 
performed according to the antibody manufacturer’s specifications. The membranes were incubated with 
primary antibodies overnight in either 5% BSA or 5% skim milk in TBS-T at 4 °C. The membranes were 
washed thrice in TBS-T. The appropriate HRP-conjugated secondary antibody was added into 5% skim 
milk in TBS-T, followed by three washes in TBS-T. The membranes were developed using a Luminata 
Crescendo Western HRP substrate (Millipore). 
   Antibodies used in this work are as follows: pCRAF (#9427), pMEK (#9154) and MEK (#8727) 
antibodies were from Cell Signaling Technology (MA, USA). BRAF (sc-55522), TPL2 (sc-373677) 
antibodies were from Santa Cruz Biotechnology (CA, USA). AAG8 (HPA018002), GAPDH (G9295) and 
the secondary HRP-conjugated anti-mouse IgG (A9044) antibodies were from Sigma (MO, USA). VIM 
(ab8978) antibody was from Abcam (MA, USA). The secondary HRP-conjugated anti-rabbit IgG antibody 
(G21234) was from Invitrogen (CA, USA). 
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2.5 Growth assay and apoptosis assay 
 
Cells was seeded in 6-well plates with triplicate cultures and treated as indicated with according periods. 
Dead cells were stained with trypan blue and total cell number was evaluated with CountessTM (Invitrogen). 
For apoptosis assay, cells were treated with indicated AAG8 antagonists for 48 hr in 3D Matrigel culture, 
and then stained with 1 nM ethidium bromide (EtBr) for 5 min. The stained DNA were observed and 
photographed under a fluorescence microscope (OLYMPUS, IX2-ILL100, Japan)  
 
2.6 Statistics  
 
All quantitative data were presented as means ± s.e.m.. Statistical significance between the control and 
treatment groups was assessed by using one way ANOVA followed by Tukey's test. Statistical significance 
was considered at the p < 0.05 level. 
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 3. Results 
 
3.1 AAG8-antagonism restricts melanoma cells  
 
Dysregulation of signalling pathways by changes of gene expression contributes to hallmarks of cancer. A 
systematic study revealed AAG8 mRNA overexpression up to above 8-fold in melanoma versus normal 
skin (Figure 2-3),69 indicating its vital roles in melanomagenesis. We wondered whether perturbing AAG8 
function could affect melanoma cell growth by investigating AAG8 antagonism in B16F1 (B16) cells, 
derived from mouse melanoma. B16 cells express high level of AAG8 exclusively in the cytosol (Figure 2-
4). Notably, B16 cells were sensitive to BD1047 (Figure 2-5), a specific AAG8 antagonist70. We observed 
dose-dependent suppressive phenotypes in 3D culture (Figure 2-6). To corroborate our results, BD1063 
(Figure 2-5), another specific AAG8 antagonist, was used to treat B16 cells in 3D culture, and similar 
effects were obtained (Figure 2-7). We further found that BD1047 or BD1063 dose-dependently induced 
apoptosis of B16 cells in 3D culture (Figure 2-8). Confirming the growth regression, growth assay showed 
that BD1047 dose-dependently suppressed cell growth, and 100 μM BD1047, a routinely used 
concentration in vitro70, dramatically decreased viable cells (Figure 2-9). 
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Figure 2-3 AAG8 mRNA is upregualted up to > 8 fold in melanoma comparing to normal skin tissues. 
(Talantov, D. et al. Clin Cancer Res, 2005) 
 
 
 
 
Figure 2-4 AAG8 cellular distribution. Immunoblot of AAG8 and LMNB in the indicated cellular fractions 
of B16 cells. LMNB serves as loading control.  
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Figure 2-5 Chemical structures of AAG8 antagonists. 
 
 
 
 
Figure 2-6 AAG8 antagonism in B16 cells of 3D culture. Phase contrast images showing B16 cells cultured 
in 3D Matrigel and treated with BD1047 of indicated concentration for 18 hr.  
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Figure 2-7 Phase contrast images showing B16 cells cultured in 3D Matrigel and treated with 50 μM 
BD1063 for 48 hr. 
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Figure 2-8 AAG8 antagonism induced apoptosis in B16 cells. B16 cells in 3D culture are treated with the 
indicated concentrations of BD1047 or BD1063 for 48 hr and stained with EtBr. 
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Figure 2-9 Growth assay with CountessTM (Invitrogen) of B16 cells of 2D culture treated with BD1047 of 
indicated concentration for 24 hr. Initial cell number = 3 × 105. n = 3. Error bars (s.e.m.) are indicated. Note: 
** p <0.01, *** p <0.001 (one way ANOVA followed by Tukey's test). 
 
 
Figure 2-10 Representative images of wound healing assay of B16 cells treated with 100 μM BD1047 or 
BD1063. Experiments were performed three times with consistent results. 
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 Additionally, metastatic progression of cancer is a complex and clinically daunting process. Metastatic 
growth in distant organs is the major cause of cancer mortality. It was observed that AAG8 antagonists 
dampened B16 cell migration, as indicated by wound healing assay. Cells treated with PBS healed the 
wound almost completely after 20 hr, in contrast, cells treated with antagonist could not (Figure 2-10). 
These data intimate the anti-tumor effects of AAG8 antagonism and highlight AAG8 antagonists as 
potential drugs for melanoma therapy.  
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 3.2 AAG8 antagonism inhibits CRAF-MEK activity  
 
Excessive MAPK pathway activation accounts for more than 90% of melanomas.71 As MEK is a mediatory 
effector downstream of RAF, its inhibitors are being tested in clinical trials for melanoma and the other 
cancers.45,59 I noticed the dose-dependent inactivation of MEK in BD1047-treated B16 cells (Figure 2-11). 
I further showed that the MEK activity decreased significantly after 3 hr of BD1047 treatment (Figure 2-
12). Similar inhibitory effect on MEK activity was also observed with BD1063 (Figure 2-13). Furthermore, 
I found that both antagonists could lead to decreased activity of CRAF, the upstream kinase of MEK45 
(Figure 2-11, 2-13). These results suggest that AAG8 antagonism restricts B16 cells through, at least partly, 
the suppression of CRAF-MEK signaling. A recent study demonstrated a positive feedback loop in which 
CRAF phosphorylation is dependent on MEK activity72. I thus speculate that AAG8 antagonism blocks this 
loop and lead to the inactivation of both of these two kinases.  
 
 
Figure 2-11 Immunoblot of pCRAF and pMEK in B16 cells treated with the indicated concentrations of 
BD1047 for 20 hr shows dose-dependent inhibition of CRAF and MEK. Mean values of pCRAF and pMEK 
versus MEK levels were labeled with control cells as standard. 
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Figure 2-12 Immunoblot of pMEK and total MEK in B16 cells treated with 100 μM BD1047 for indicated 
time. Mean values of pMEK versus MEK levels were labeled with control cells as standard. 
 
 
 
 
Fggure 2-13 Immunoblot of pCRAF and pMEK in B16 cells treated with the indicated concentrations of 
BD1063 for 20 hr. Mean values of pCRAF and pMEK versus MEK levels were labeled with control cells 
as standard. 
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 3.3 B16 cells can generate drug resistance to AAG8 antagonists 
 
To model the emergence of BD1047 resistance, B16 cells were continuously exposed to 100 μM BD1047, 
an approach that more closely represents the clinical situation.73 A BD1047-resistant B16 cell line (termed 
B16BR) was established after 57 days. B16BR cells expressed comparable AAG8 level with B16 cells 
(Figure 2-14), however, these cells exhibited altered morphology in both 2D and 3D cultures (Figure 2-15, 
16). For validating whether these BD1047-resistant cells are also less sensitive to BD1063, both cell lines 
were queried for sensitivity to BD1063 and BD1047, respectively. Importantly, BD1063, as well as 
BD1047, significantly suppressed B16 cell growth as compared with B16BR cells, confirming the 
refractory of B16BR cells to AAG8 antagonists (Figure 2-17). Consistently, AAG8 antagonist treatment 
failed to restrict B16BR cell migration (Figure 2-18). These data depict an AAG8 antagonist-resistant model 
which is valuable for further exploration of mechanisms of resistance. 
 
 
 
Figure 2-14 Immunoblot of AAG8 in B16BR cells versus B16 cells. 
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Figure 2-15 Phase contrast images showing different phenotypes of B16 and B16BR cells in 2D (upper) 
and 3D (lower) cultures, respectively. 
 
Figure 2-16 Comparision of the length/width ratio of B16 versus B16BR cells in 2D culture. 30 cells were 
randomly selected from the photo in Figure 2-15 (2D) and analyzed with ImageJ  software. 
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Figure 2-17 Growth assay with CountessTM (Invitrogen) of B16 or B16BR cells treated with 100 μM 
BD1047 or BD1063 for 96 hr. Initial cell number = 105. n = 3. Error bars (s.e.m.) are indicated. Note: * p 
<0.05, *** p <0.001 (one way ANOVA followed by Tukey's test). 
 
Figure 2-18 Representative images of wound healing assay of B16BR cells treated with 100 μM BD1047 
or BD1063. Experiments were performed three times with consistent results. 
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 3.4 MEK confers B16BR cells to AAG8 antagonist resistance 
 
Various drug resistant mechanisms in melanoma have been argued recently.45,59,60,73,74 Although 
upregulation and spliced variants of BRAF are often reported in drug-resistant melanoma models,59,73 I did 
not detect the aberrant expression of BRAF (Figure 2-19), excluding the possibility of BRAF expression-
related resistance. To determine the resistant mechanisms in our model, I tested whether it is associated 
with decreased sensitivity of MEK activity to AAG8 antagonists. I evaluated the difference between B16 
and B16BR cells by measuring pMEK level 6 hr after BD1047 treatment. Whereas pMEK was suppressed 
in B16 cells, it was almost unaffected in B16BR cells (Figure 2-19). Concurrently, as I observed the 
mesenchymal-like phenotype of B16BR cells (Figure 2-15), the mesenchymal marker Vimentin (VIM) was 
compared between these cell lines, indicating there might be epithelial-to-mesenchymal transition (EMT) 
during the generation of the drug resistance. Neither BD1047 nor BD1063 treatment affected VIM 
expression, however, VIM expression increased in B16BR cells apparently (Figure 2-19). I conclude that 
B16BR cells are aggressive mesenchymal melanoma cells and are resistance due to the refractory MEK 
activity. Given that Johannessen et al. identified TPL2 as a MAPK pathway agonist that activates MEK 
independent of RAF signaling and drives resistance to RAF inhibition in melanoma,75 I hypothesized that 
TPL2 might be upregulated in B16BR cells. Strikingly, I found a dramatically diminished expression level 
of TPL2 in these cells (Figure 2-19). This unanticipated and disparate finding means that TPL2 is not 
essential for the enhanced MEK activity in AAG8 antagnosts-resistant melanoma but might serve as a tumor 
suppressor under this circumstance.  
   Regarding the suppression of CRAF-MEK activity by AAG8 antagonism, I tested whether the upstream 
CRAF is also refractory to AAG8 antagonism. BD1047 or BD1063 treatment resulted in decreased CRAF 
phosphorylation in B16 cells, albeit modestly, but not in B16BR cells (Figure 2-19). Considering this 
modest change might be due to the shorter time (6 hr) treatment, I increased the treatment period to 20 hr 
for both cell lines. Apparently, B16BR cells did respond to BD1047 treatment at higher dose (300 μM), 
however, the degree of pCRAF and pMEK inhibition was less profound versus B16 cells under the same 
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 conditions (Figure 2-20). These data confirmed that refractory CRAF-MEK activity confers B16BR cell 
resistance to AAG8 antagonism. 
 
 
Figure 2-19 Immunoblot comparing the indicated proteins in B16 and B16BR cells treated with PBS, 100 
μM BD1047 or 100 μM BD1063 for 6 hr. 
 
 
Figure 2-20 Immunoblot of pCRAF and pMEK shows the refractory CRAF and MEK activity in B16BR 
cells versus B16 cells treated with indicated concentrations of BD1047 for 20 hr. Mean values of pCRAF 
and pMEK versus MEK levels were labeled with control cells as standard. 
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    RAS activity was next examined to investigate whether the reactivation of CRAF-MEK signaling is due 
to RAS reactivation. Surprisingly though, while BD1047 dramatically reduced RAS-GTP level in B16 cells, 
RAS activation was largely abrogated in B16BR cells (Figure 2-21). These data suggest that while RAS-
CRAF-MEK signaling is efficiently suppressed by AAG8 antagonism in B16 cells, some other pathways, 
rather than RAS, have been triggered to substitute the function of RAS and maintain the refractory CRAF-
MEK activity, which contributes to the drug resistance of B16BR cells (Figure 2-22). Though mutationally 
activated RAS is a common event in carcinogenesis76,77, our findings suggest that RAS mutation might not 
be involved in AAG8 antagonists-induced drug resistance. These data also reveal the tricky mechanisms 
which cancer cells lacking oncogenetic RAS employ to generate drug resistance. 
 
 
Figure 2-21 Immunoblot of pCRAF, pMEK, MEK, RASGTP, RAS and GAPDH in B16 versus B16BR 
cells treated with PBS or 100 μM BD1047 for 12 hr.  
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Figure 2-22 A hypothetic model that illustrates the mechanisms of AAG8 antagonism in melanoma cells. 
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 3.5 Tandem AAG8-MEK inhibition in B16BR cells 
 
Based on the finding that B16BR cells maintain refractory MEK activity, I supposed that combined 
inhibition of AAG8 and MEK could limit B16BR cell growth more efficiently. Substantiating this 
conjecture, I combined BD1047 and PD901 (hereafter PD901), a selective MEK inhibitor currently in 
clinical cancer trials which blocks MEK1 at values of 1 μM in vitro.78 However, MEK inhibitors have often 
been reported for drug resistance and dose-limiting side effects, resulting the compromised efficacy.71 To 
more closely mimic the clinical situation and decrease the cytostatic activity, I used a much lower dose at 
50 nM PD901 for modeling our drug combination strategy. Intriguingly, whereas PD901 showed similar 
growth inhibitory effect with BD1047, combined treatment significantly decreased cell numbers, 
comparing with either BD1047 or PD901 treatment (Figure 2-23, 24). Because upregulation of 
counteracting signaling cascades as a direct response to MEK inhibition limits the efficacy of MEK 
inhibitors in melanoma patients,74 our results pinpoint the collaborative effect of AAG8 antagonism and 
MEK inhibition and suggest AAG8 plus MEK inhibitory combination therapy as a potential therapeutic 
strategy for melanoma. This drug combination uses very low dose of MEK inhibitor and has critical 
implications for reducing the drug side effects during clinical melanoma prevention. 
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Figure 2-23 Tandem AAG8-MEK inhibition in B16BR cells treated with 100 μM BD1047 and/or 50 nM 
PD901 for 65 hr. Initial cell number = 5 × 105. n = 3. Error bars (s.e.m.) are indicated. Note: ** p <0.01, 
*** p <0.001 (one way ANOVA followed by Tukey's test). 
 
 
Figure 2-24 Phase contrast images of B16BR cells as described in (B). 
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 4. Discussion 
 
AAG8 is a protein profoundly investigated in neurology.34 Previous studies have shown its ER-associated 
functions in lens37 and mouse Leydig cells15, however, how AAG8 correlates with carcinogenesis remains 
unidentified. Our studies uncover the molecular clue that AAG8 antagonism exhibits anti-melanoma effects 
through inhibition of the RAS-CRAF-MEK signaling activity. In agreement with the recent notion that 
CRAF S338 phosphorylation is dependent on MEK activity, I theorize that AAG8 antagonism could block 
this positive feedback loop to restrict melanoma cell growth. I also found that the melanoma cells got 
resistant during a consistent exposure to AAG8 antagonist. This is noteworthy as it implies that melanoma 
is incurable due to the acquisition of drug resistance, and the B16BR cell line provide a proper model for 
investigation of resistance mechanisms.  
   I employed two specific AAG8 antagonists in the micromolar range, the routinely used concentrations in 
vitro69, for modeling the AAG8 antagonism and drug resistance in melanoma cells, though it is a higher 
dose comparing to current anti-tumor drugs45. Promisingly, other synthesized AAG8 ligands have been 
reported to specifically bind to AAG8 in the nanomolar range15. Further efforts are needed to determine 
whether the anti-tumor ability of AAG8 antagonists and the resistance could be translated in vivo, because 
this may have implications for developing AAG8 antagonists as novel anti-cancer drugs.  
   I further demonstrated the underlying resistance mechanisms of B16BR cells. I found that these cells are 
much less sensitive to AAG8 antagonists, and this is due to, at least partly, the refractory CRAF-MEK 
activity in these cells. This finding is consistent with the melanoma model that is resistant to RAF 
inhibitor,73 suggesting MEK as a common culprit in maintaining melanoma survival in drug-existing 
microenvironment. Nevertheless, beyond our expectation, B16BR cells harbor little, rather than redundant, 
RAS activity, despite their sustained CRAF-MEK signaling. Consistent with previous rationales,74,75,79 our 
findings suggest the existence of alternative signaling cascades which have been triggered in B16BR cells 
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 to maintain the refractory CRAF-MEK activity. Our data reveal the exquisite modulation mechanisms of 
cancer cells for survival in response to harsh microenvironment (such as chemotherapeutic drugs). 
   Based on these molecular findings, I proposed a drug combination strategy, i.e. BD1047-PD901 
combination, for tandem AAG8-MEK inhibition in melanoma cells. This combination efficiently limits the 
growth of B16BR cells, indicating the cooperative effects of these two inhibitors. In addition, despite 
efficient suppression of MEK activity by MEK inhibitors, cytostatic side effects restrict their efficacy for 
clinical trial.71 I showed that AAG8 antagonist combined with even very low concentration (50 nM) of 
PD901 can significantly decrease the viability of refractory B16BR cells, suggesting that tandem AAG8-
MEK inhibition is a powerful therapeutic approach for increasing the antitumor efficacy and decreasing the 
drug resistance of each single inhibitor.  
   This research has focused on the mechanistic insights into AAG8 antagonists-induced MEK inhibition 
and drug resistance. The importance of this study is to provide precise concept and methodology for 
preliminarily investigating the pharmacological and drug-resistant mechanisms of cancer in vitro. AAG8 
antagonists BD1047 and its analogue BD1063 were used for in vitro modeling the AAG8 functions in 
melanoma. Moreover, our findings provide implications and encourage the medical chemists to improve 
the specificity and binding affinity of these antagonists for the further feasible clinical use. 
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 Chapter 3  AAG8 Promotes Carcinogenesis through STAT3 Activation 
 
1. Introduction 
 
The STAT (signal transducer and activator of transcription) family consists of seven members: STAT1, 
STAT2, STAT3, STAT4, STAT5A, STAT5B, and STAT6. STATs are pivotal in modulating cellular 
functions in response to cytokines, interferons, and various growth factors, which activate JAKs (Janus 
kinases), leading to key tyrosine phosphorylation on their receptors. JAKs activation allows the binding of 
STATs via their SH2 domains to these phosphotyrosine docking sites. STATs are in turn tyrosine 
phosphorylated, thus allowing their dimerization and activation. STATs have been shown to be controlled 
by several negative regulatory mechanisms. Notably, the SOCS (suppressor of cytokine signalling) family 
negatively regulates STATs activation 80. STAT3 is a well-known transcription factor that has been 
intensively investigated in cancer and immunity 81,82. Upon phosphorylation at Y705, activated STAT3 
translocates into the nucleus to initiate transcription. STAT3 hyperactivation is a feature of the majority of 
solid cancers. However, how STAT3 activation is regulated is not fully understood.  
Despite the previous notably described findings of AAG8 in neuroscience, the importance of AAG8 in 
cancer has rarely been noticed. In chapter 2, I discovered that AAG8 antagonists potentially inhibits 
melanoma cells growth, however, the lack of gain- or loss-of-function studies has so far precluded a clear 
understanding of the rationale of AAG8 in carcinogenesis. In this chapter, I explored the intrinsic roles of 
AAG8 in cancer cells and found that AAG8 promoted carcinogenesis both in vitro and in vivo. We further 
characterized AAG8, for the first time to our knowledge, as a STAT3 activator and demonstrated that it 
alternatively activated STAT3 in addition to IL6/JAK pathway. 
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 2. Materials and methods 
 
2.1 Cell lines and reagents 
 
DLD-1, HCT116, PANC1, AGS, MKN7, MSTO211H and B16 cell lines were obtained from American 
Type Culture Collection (USA). COLO205 cell line was purchased from RIKEN Cell Bank (Japan). Cell 
culture was maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% fetal 
bovine serum (FBS, Life Technologies, Carlsbad, CA, USA) in a standard incubator at 37°C with 5% CO2. 
AAG8 antagonists BD1047 and BD1063, and AAG8 agonist PRE084 were purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA, USA). MatrigelTM basement membrane matrix was from BD Bioscience 
(Bedford, MA, USA). Recombinant human IL-6 was from Genzyme-Techne (Minneapolis, MN, USA). 
Gemcitabine was from SIGMA (St Louis, MO, USA). JSI124, YM155, Ruxolitinib, JAK Inhibitor I and 
JAK Inhibitor VI were included in the SCADS Inhibitor Kits. 
 
2.2 3D culture  
 
3D on-top culture of cancer cells was as described previously with some modifications 67. Briefly, surface 
of 6-well plates was coated with pre-thawed Matrigel (500 μl/well) with a pipette tip. For each well, 3 × 
105 or 106 cells were resuspended in 3 ml of complete Dulbecco’s Modified Eagle’s Medium containing 5% 
Matrigel and pipetted onto the pre-coated surface. Chemicals were added into the medium as indicated. 
Cells were then cultured for the indicated days before further assays. Cells were observed and photographed 
under a phase contrast microscope (OLYMPUS, Tokyo, Japan). 
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 2.3 Establishing stable cell lines 
 
For AAG8 overexpression, SIGMAR1 gene was cloned from the cDNA of DLD-1 cells with the forward 
primer 5’-ACCCAAGCTGGCTAGAATGCAGTGGGCCGTG-3’ and reverse primer 5’-
GTGGATCCGAGCTCGTCAAGGGTCCTGGCCAAAG-3’, and subcloned into pcDNA3.1 vector (Life 
Technologies) between NheI and KpnI sites. DLD-1 and AGS cells were transfected with empty vector or 
the plasmid expressing AAG8 with Lipofectamine LTX with Plus reagent (Life Technologies) according 
to the manufacture’s instructions. 48 h after transfection, cells were selected by 700 μg/ml G418 (WAKO, 
Wako, Japan). For gene knockdown, we employed the RNA polymerase II promoter U6 in pLKO.1 vector 
to express shRNA targeting the 5’-CCTCAACCCAGCAGCAATTTG-3’ sequence of SIGMAR1 gene. 
Lentivirus incorporating with shRNA was generated in HEK293T cells by combining packing plasmid 
pCMV-dR8.91, envelope plasmid VSV-G (gifts from Dr. Kenneth Rock, University of Massachusetts 
Medical School, Worcester, MA) and the pLKO.1 plasmids. DLD-1 cells were infected with the lentivirus 
and selected by 3 μg/ml puromycin (SIGMA). HCT116 and AGS cells were transfected directly with the 
shRNA plasmids with Lipofectamine LTX with Plus reagent (Invitrogen) according to the manufacture’s 
protocol. 48 h after transfection, cells were selected by 1 μg/ml puromycin (SIGMA). A scramble shRNA 
plasmid (kindly provided by Dr. David Sabatini, Addgene plasmid 1864) was used as control 83. 
 
2.4 Transient API4 knockdown 
 
DLD-1 cells were transfected with the pLKO.1 shRNAs targeting the 5’-
CGTCCGGTTGCGCTTTCCTTT-3’ sequence (shAPI4-1) and the 5’-CCGCATCTCTACATTCAAGAA-
3’ sequence (shAPI4-2) of BIRC5 (API4) gene, respectively, with Lipofectamine LTX with Plus reagent 
(Invitrogen) according to the manufacture’s protocol. A scramble shRNA plasmid was used as control. 
Seventy-two hours after transfection, cells were treated as indicated. 
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2.5 Growth assay and apoptosis assay 
 
For growth assay, dead cells were stained with trypan blue and total cell number was evaluated with 
CountessTM (Life Technologies). For apoptosis assay, cells were treated with chemicals as indicated in 3D 
Matrigel culture, and then stained with 1 nM ethidium bromide (EtBr) for 5 min. The stained DNA were 
observed and photographed under a fluorescence microscope (OLYMPUS).  
 
2.6 Xenografts 
 
Animal experiments were performed in accordance with the policies of the Animal Ethics Committee of 
the University of Tokyo. Female BALB/c nu/nu mice (4 weeks of age) were purchased from the Sankyo 
Labo Service Corporation. Three million cells with Matrigel in 100 μl were injected into the flank of each 
mouse subcutaneously and tumors were measured as described previously 84. 
 
2.7 Western blot 
 
Cells were lysed with Laemmli buffer and each lysate sample was loaded into two adjacent lanes, if 
indicated, of a 10% polyacrylamide gel for minimizing loading differences. For PKM2 detection, 
cytoplasmic and nuclear fractions were prepared with NE-PER Nuclear and Cytoplasmic Extraction 
Reagents (Thermo Scientific, Rockford, RL, USA) according to the manual’s instructions. Proteins were 
separated at 30 mA and transferred onto PVDF membranes (Millipore, Darmstadt, Germany). Membranes 
were blocked for 1 h at room temperature using 5% skim milk or 5% BSA (for phosphorylation detection) 
in TBS-Tween (TBS-T). Western blot analysis was performed according to the antibody manufacturer’s 
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 specifications. The membranes were incubated with primary antibodies overnight in either 5% BSA or 5% 
skim milk in TBS-T at 4 °C. The membranes were washed thrice in TBS-T. The appropriate HRP-
conjugated secondary antibody was added into 5% skim milk in TBS-T, followed by three washes in TBS-
T. The membranes were developed using a Luminata Crescendo Western HRP substrate (Millipore). 
Antibodies used in this work are as follows: pSTAT3 (#9145) antibodies were from Cell Signalling 
Technology (Danvers, MA, USA). STAT3 (sc-482), antibodies were from Santa Cruz Biotechnology. 
AAG8 (HPA018002) and GAPDH (G9295) antibodies were from SIGMA. API4 (NB500-201H) and 
LMNB (NBP1-19804) antibodies were from NOVUS (Littleton, CO, USA). PKM2 (ab150377) antibody 
was from abcam (Cambridge, MA, USA). The secondary HRP-conjugated anti-rabbit IgG antibody 
(G21234) was from Life Technologies. 
 
2.8 Statistical analysis 
 
All statistical analysis was performed using Origin 8 Software. Error bars indicate standard errors of the 
mean (S.E.M.). Time courses or dose dependence were analyzed by two-tailed unpaired t-test or one-way 
ANOVA followed by appropriate post hoc test. 
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 3. Results 
 
3.1 Oncogenetic AAG8  
 
We firstly observed that specific AAG8 antagonist BD1047 induced growth-suppressive phenotype of 
colorectal COLO205 cancer cells (Figure 3-1), pancreatic PANC1 cancer cells and gastric AGS cancer cells 
(Figures 3-2, 3-3) in 3D Matrigel culture. Moreover, BD1047 potently suppressed mesothelioma 
MSTO211H cell growth in 3D culture, by contrast, AAG8 agonist PRE084 failed to suppress their growth 
and tube formation, though different phenotype was observed (Figure 3-4). In addition, BD1047 induced 
apoptosis of 3D-cultured COLO205 cells (Figure 3-5). BD1047 also dose-dependently suppressed the 
growth of colorectal COLO205 and DLD-1 cancer cells, as well as gastric MKN7 cancer cells (Figure 3-
6).  
 
 
 
 
Figure 3-1 Phase contrast images showing COLO205 cells cultured in 3D Matrigel and treated with or 
without 100 μM BD1047 (AAG8 antagonist) for 48 h. 
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Figure 3-2 Phase contrast images of PANC1 and AGS cells cultured in 3D Matrigel and treated as indicated. 
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Figure 3-3 Phase contrast images of AGS cells cultured in 3D Matrigel and treated as indicated. 
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Figure 3-4 Phase contrast images MSTO-211H cells cultured in 3D Matrigel and treated as indicated. 
 
 
Figure 3-5 COLO205 cells in 3D culture were treated with 10 μM PRE084 (AAG8 agonist) or BD1047 of 
indicated concentrations for 72 h and stained with EtBr for indicating apoptosis. 
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 Figure 3-6 Growth assay with CountessTM (Invitrogen) of COLO205, DLD-1 and MKN7 cells in 2D culture 
treated with BD1047 of indicated concentrations or 10 μM PRE084 for 50 h. DLD-1: initial cell number = 
5 × 105; n = 4. COLO205: initial cell number = 2 × 105. n = 4; MKN7: initial cell number = 5 × 105. n = 3. 
Error bars (s.e.m.) are indicated. * p < 0.05, ** p < 0.01, *** p < 0.001 (one way ANOVA followed by 
Tukey's test). 
 
Gain- and loss-of-function approaches were next employed for further confirmation. AAG8 
overexpression promoted proliferation of both DLD-1 (Figure 3-7) and gastric AGS (Figure 3-8) cancer 
cells. In line with this, AAG8 knockdown with short hairpin RNA (shRNA) delayed DLD-1 cell 
proliferation (Figure 3-9), and suppressed AGS cell growth in 3D culture (Figures 3-10, 3-11), which 
closely mimicked the phenotype changes observed with AAG8 antagonist (Figure 3-2). Interestingly, 
although AAG8 knockdown resulted in little to no alternations to the morphogenesis of colorectal HCT116 
cancer cells in 3D culture, it increased their sensitivity to gemcitabine, a clinical cancer drug (Figures 3-12, 
3-13). In agreement with the data in vitro, AAG8 knockdown slowed xenograft tumor formation of DLD-
1 cells in vivo (Figure 3-14). These results collectively illustrate the tumor-promoting roles of AAG8 and 
imply that AAG8 serves as an oncoprotein and indicate AAG8 as a potential target for tumor chemotherapy. 
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Figure 3-7 Immunoblot of AAG8 and proliferation assay of DLD-1 cells with stable overexpression. Total 
lysates from control and stable cell lines were immunoblotted with AAG8 antibody; GAPDH served as 
loading control. Cell number was counted every 3 days. Initial cell number = 5 × 103. n = 3. Error bars 
(s.e.m.) are indicated. * p < 0.05, *** p < 0.001 (two-tailed unpaired t-test). 
 
Figure 3-8 Enhanced AGS cell proliferation by AAG8 overexpression. Immunoblot of AAG8 and 
proliferation assay of AGS cells with stable AAG8 overexpression. Total lysates from control and stable 
overexpression cell lines were immunoblotted with AAG8 antibody; GAPDH served as the loading control. 
Cell number was counted every 3 days. Initial cell number = 5 × 103. n = 3. Error bars (s.e.m.) are indicated. 
** p <0.01, *** p <0.001 (two-tailed unpaired t-tests). 
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Figure 3-9 Immunoblot of AAG8 and proliferation assay of DLD-1 cells with stable AAG8 knockdown 
(right). Total lysates from control and stable knockdown cell lines were immunoblotted with AAG8 
antibody; GAPDH served as loading control. Cell number was counted every 3 days. Initial cell number = 
5 × 104. n = 3. Error bars (s.e.m.) are indicated. * p < 0.05, *** p < 0.001 (two-tailed unpaired t-test). 
 
 
 
Figure 3-10 Immunoblot of AAG8 in stable AAG8-knockdown AGS cells. Total lysates from control and 
stable knockdown cell lines were immunoblotted with AAG8 antibody; GAPDH served as the loading 
control. 
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Figure 3-11 Phase contrast images showing AAG8-knockdown AGS cells cultured in 3D Matrigel. 
 
 
Figure 3-12 Immunoblot of AAG8 in stable AAG8-knockdown HCT116 cells. Total lysates from control 
and stable knockdown cell lines were immunoblotted with AAG8 antibody; GAPDH served as the loading 
control. 
 
 
 
Figure 3-13 Phase contrast and immunofluorescence images of HCT116 cells treated with or without 100 
nM gemcitabine for 72 h and then stained with EtBr for indicating apoptosis. 
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Figure 3-14 Three million DLD-1 cells were injected subcutaneously into athymic nude mice. 
Representative pictures of mice are shown in left panel and quantitative measurements are shown in right. 
n = 7 (shCtrl), n = 8 (shAAG8). Error bars (s.e.m) are indicated. ** p <0.01 (one way repeated ANOVA 
followed by Tukey's test).  
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 3.2 Identification of AAG8 as a STAT3 activator 
 
For explaining the underlying molecular mechanisms of AAG8 in promoting carcinogenesis, I 
unanticipatedly discovered STAT3 inactivation in both PANC1 (Figure 3-15) and AGS cells treated with 
BD1047 in a dose-dependent manner (Figure 3-16). Time-dependent assay revealed that STAT3 activity 
began to decrease 3 hours after BD1047 treatment and was largely suppressed after 6 hours in mouse 
melanoma B16 cells (Figure 3-17). I supposed that AAG8 may act as a STAT3 activator to enhance cancer 
cell proliferation. Supporting this hypothesis, I found that STAT3 Y705 phosphorylation level was 
increased by ectopic AAG8 expression in DLD-1 cells (Figure 3-18, left). Consistently, AAG8 knockdown 
decreased STAT3 activation in both DLD-1 cells (Figure 3-18, right), as well as in AGS cells (Figure 3-
19). These findings convincingly indicate AAG8 as an upstream STAT3 activator. 
 
 
Figure 3-15 Immunoblot of pSTAT3 and STAT3 in PANC1 cells in 3D culture treated with 100 μM 
BD1047 for 48 h. 
 
 
 
Figure 3-16 Immunoblot of pSTAT3 and STAT3 in AGS cells in 2D culture treated with BD1047 of 
indicated concentrations for 24 h. 
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Figure 3-17 Immunoblot of pSTAT3 and STAT3 in B16 cells in 2D culture treated with 100 μM BD1047 
for different periods of time (0, 1, 3, 6, 9 and 12 h). Total lysates from control and treated cells were 
immunoblotted with pSTAT3 antibody; STAT3 served as loading control. 
 
 
 
Figure 3-18 Immunoblot of pSTAT3 and STAT3 in DLD-1 cells with stable AAG8 overexpression (left 
panel) or stable AAG8 knockdown (right panel). Mean values of pSTAT3 versus STAT3 levels were 
labeled with control cells as standard. 
 
Figure 3-19 Immunoblot of pSTAT3 and STAT3 in stable AAG8-knockdown AGS cells. Mean values of 
pSTAT3 versus STAT3 levels were labeled with control cells as standard. Total lysates from control and 
treated cells were immunoblotted with pSTAT3 antibody; STAT3 served as loading control. 
 
 
67 
 
 3.3 Dual STAT3 activation by AAG8 and JAK signalling 
 
I next performed a SCADS (screening committee of anticancer drugs) screening using DLD-1 cells stably 
expressing both AAG8 and a luciferase STAT3 reporter, in which STAT3 activity could be monitored after 
drug treatment. Among 364 chemicals with 232 targets (Table 1), an API4 (apoptosis inhibitor 4) inhibitor, 
YM155, was found to dramatically (fold change > 20) decrease STAT3 activity in these cells (Figure 3-
20). This is consistent with the published data that YM155 reduced STAT3 phosphorylation in PANC1 
cells 85, and suggested that YM155 might block STAT3 activation either dependent on or independent of 
AAG8-related signalling. To further disentangle this event, DLD-1 cells with stable AAG8 knockdown 
were treated with or without YM155 for 12 h, followed by IL6 stimulation, because the IL6-JAK-STAT3 
pathway has been well established previously. As a result, IL6-induced robust STAT3 activation was 
largely abolished by YM155 treatment (Figure 3-21), confirming the STAT3 inhibitory effect of YM155 
in SCADS screening and suggesting that YM155 disturbs the signalling activities which are indispensable 
for IL6-induced STAT3 activation. In contrast, AAG8 knockdown contributes no change to IL6-induced 
STAT3 phosphorylation level (Figure 3-21), meaning that AAG8 activates STAT3 beyond IL6-dependent 
manner. Substantiating this conjecture, specific AAG8 antagonists BD1047 or its analog BD1063 failed to 
decrease IL6-induced STAT3 activation in DLD-1 cells (Figure 3-22). Surprisingly, AAG8 knockdown 
further diminished the remaining pSTAT3 in YM155-treated cells (Figure 3-21). Based on the above 
findings, I hypothesized that AAG8 knockdown could also decrease STAT3 activity in cells with inhibition 
of IL6/JAK pathway. As expected, similar results to Figure 3-21 was obtained with two JAK inhibitors, 
JAK inhibitor I and Ruxolitinib, respectively (Figure 3-23). 
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Target Compound 
antitumor (thymidylate synthetase) 5-FU 
antitumor (aminopeptidase B) Bestatin 
antitumor (DNA) Bleomycin sulfate 
antitumor (DNA) Cisplatin 
antitumor (DHFR) Methotrexate 
antitumor (DNA) Mitomycin C 
antitumor (tubulin) Vinblastine sulfate 
antitumor  (tubulin) Paclitaxel 
antitumor (AR) Flutamide 
antitumor (DNA) Daunorubicin, HCl 
antitumor (DNA) Doxorubicin, HCl 
antitumor (ER) Tamoxifen, citrate 
antitumor (RNA) Actinomycin D 
antitumor (topo I) Camptothecin 
antitumor (topo I/II) Aclarubicin 
antitumor (topo II) Etoposide (VP-16) 
actin filament Cytochalasin D 
adenylcyclase 2',5'-dideoxyadenosine 
AKT AKT inhibitor 
AKT NL-71-101 
Bcr-Abl AG957 
CAMKII KN93 
caspase Z-VAD-FMK 
CDC2 Kenpaullone 
CDK2 Purvalanol A 
CDK4 3-ATA 
CDKs Olomoucine 
CKII TBB 
COX-1 Sulindac sulfide 
COX-1 Valeryl salicylate 
COX-2 NS-398 
COX Sodium salicylate  
cyclicphosphodiesterase Theophylline 
DNA methyltransferase Azacytidine 
DNA polymerase Aphidicolin 
EGFR AG1478 
EGFR, topoII Genistein 
farnesyltransferase Manumycin A 
farnesyltransferase FTI-276 
Flk-1 SU1498 
geranylgeranyltransferase I GGTI-286 
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 GR Dexamethasone 
GSK-3 GSK-3 inhibitor II 
HDAC Scriptaid 
HDAC Trichostatin A 
HER2 (erbB2/neu), EGFR AG825 
protein synthesis Cycloheximide 
HMG-CoA reductase Lovastatin 
HSP90 Radicicol 
HSP90 17-AAG 
IGF-1R AG1024 
iNOS 1400W, HCl 
iNOS AMT, HCl 
Jak-2 AG490 
Jak-2 Cucurbitacin I 
JNK SP600125 
lck (p56), TYK Damnacanthal 
MEK PD 98059 
MEK U0126 
methionine aminopeptidase Fumagillin 
MMP GM 6001 
NF-kB N-Acetyl-L-cysteine 
NOS Aminoguanidine, HCl 
NOS L-NMMA 
p38 (MAPK) PD169316 
p38 (MAPK) SB 203580 
p70 S6K Rapamycin 
PARP NU1025 
PARP-1 Benzamide 
PC-PLC D609 
PDE IBMX 
PDE (cAMP) Ro-20-1724 
PDE (cGMP) Zaprinast 
PDGFR AG1296 
PI3K LY294002 
PI3K Wortmannin 
PKA H-89, HCl 
PKC Bisindolymaleimide I, HCl 
PKC, PKA H-7 
PKC, PKA, PKG, MLCK Staurosporine 
PLA2 cPLA2inhibitor 
PLA2 OBAA 
PP2A Cantharidin 
PP2A Cytostatin 
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 PP2B/cyclophilin Cyclosporin A 
PP2B/FKBP FK-506 
proteasome MG-132 
proteasome Lactacystin 
ribonucleotide reductase Hydroxyurea 
ROCK HA1077 
ROCK Y27632 
Src, Fyn, Lck PP1 (analog) 
Src, Fyn, Lck PP-H 
tubulin depolymerization Nocodazole 
tyr phosphatase (PTP) Dephostatin 
p53 Pifithrin-a (cyclic) 
p53 activator PRIMA-1 
5α-reductase Finasteride 
aromatase Aminoglutethimide 
aromatase Formestane 
progesterone receptor Mifepristone 
acetyl-CoA carboxylase (ACC)  TOFA 
aminopeptidase A Amastatin 
aminopeptidase M Actinonin 
F1-ATPase Oligomycin 
V-ATPase Bafilomycin A1 
Bcl-2 HA 14-1 
Bcl-XL BH3I-1 
Burton's tyrosine kinase(BTK) LFM-A13 
Burton's tyrosine kinase(BTK) Terreic acid 
calpain E-64d 
calpain, cathepsin B, L ALLN 
cathepsin B  CA-074 
cathepsin D Pepstatin A 
cathepsin G Z-GLF-CMK 
CCR2  RS 102895 
CCR3 SB 328437 
CXCR2 SB 225002 
CXCR4  AMD3100 octahydrochloride 
Cdc25 NSC95397 
Cdc25A SC-αασ9 
Na channel Amiloride 
Na channel Lidocaine 
Na ionophore Monensin 
Na/K ATPase Ouabain 
Na/K/Mg ATPase Sanguinarine 
K channel Glibenclamide 
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 K channel Dequalinium 
K channel opener Diazoxide 
K ionophore Valinomycin 
K ionophore Nigericin 
Ca channel Diltiazem 
Ca channel Nifedipine 
Ca channel, MDR Verapamil 
MDR PGP-4008 
BCRP Fumitremorgin C 
Ca ionophore A23187 
Ca ionophore Ionomycin 
Ca-ATPase Thapsigargin 
Ca-ATPase t-Butylhydroquinone (BHQ) 
Cl channel N-phenylanthranilic acid 
Cl channel DIDS 
Chk 1 SB 218078 
Chk 1, 2 Debromohymenialdisine (DBH) 
mitochondrial complex I Rotenone 
mitochondrial complex III Antimycin A1 
CRM1 Leptomycin B* 
DAG kinase R59022 
DAG kinase Dioctanoylglycol 
DAG lipase RHC80267 
DAG acyltransferase (DGAT) Xanthohumol 
fatty acid synthase (FAS)  C75 
FAS Cerulenin 
glycosylation Tunicamycin 
glucosidase I, II Deoxynojirimycin 
a-mannosidase Swainsonine 
guanylate cyclase LY 83583 
guanylate cyclase ODQ 
HAT Anacardic acid 
HIF Chetomin 
HIF-1a hydroxylase Dimethyloxalylglycine 
kinesin Eg5 HR22C16 
kinesin Eg5 Monastrol 
lipoxygenase Nordihydroguaiaretic acid (NDGA) 
12, 15-lipoxygenase ETYA 
12-lipoxygenase Baicalein 
Mdm2 Nutlin-3 
Mdm2 MDM2 inhibitor 
monoamine oxidase Phenelzine 
monoamine oxdase B Deprenyl 
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 mitochondrial permeability transition pore (MPTP)  Decylubiquinone 
MPTP  Ro 5-4864 
MPTP opener Lonidamine 
myosin light chain kinase ML-7 
O6-methylguanine-DNA methyltransferase (MGMT)  Benzylguanine 
ornithine decarboxylase (ODC) DFMO 
PKG KT 5823 
PKG Rp-8-CPT-cGMPS 
PPAR-a MK 886 
PPAR-a activator Clofibrate 
PPAR-g BADGE 
PPAR-g activator Troglitazone 
reverse transcriptase AZT 
reverse transcriptase Nalidixic acid 
RNA polymerase a-Amanitin 
telomerase MST-312 
telomerase b-Rubromycin 
TGF-b receptor SB 431542 
spermidine/spermine N1-acetyltransferase (SSAT) 
activator N1,N12-Diethylspermine (BESpm) 
sphingosine N-acyltransferase Fumonisin B1 
AK ABT-702 
AKT Akt Inhibitor IV 
AKT Akt Inhibitor VIII, Isozyme-Selective, Akti-1/2 
AKT Akt Inhibitor XI 
AMPK compound C 
ATM ATM/ATR kinase inhibitor 
ATM ATM kinase inhibitor 
Aurora Aurora kinase/cdk inhibitor 
Aurora Aurora kinase inhibitor II 
Aurora Aurora kinase inhibitor III 
Bcr-abl AG957 
BTK LFM-A13 
BTK Terreic acid 
CAMKII KN-93 
CAMKII KN-62 
CAMKII Lavendustin C 
CDK Kenpaullone 
CDK purvalanol A 
CDK Olomoucine 
CDK Alsterpaullone, 2-cyanoethyl 
CDK Cdk1/2 inhibitor III 
CDK Cdk2/9 inhibitor 
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 CDK NU6102 
CDK Cdk4 inhibitor 
CDK NSC625987 
Chk SB218078 
Chk isogranulatimide 
Chk Chk2 inhibitor 
Chk Chk2 inhibitor II 
CK Ellagic acid 
CK TBB 
CK DMAT 
CK D4476 
Clk TG003 
DGK Diacylglycerol kinase inhibitor II 
DNA-PK IC60211 
eEF2 TX-1918 
EGFR BPIQ-Ⅱ 
EGFR AG1478 
EGFR AG490 
FGFR SU4984 
FGFR SU5402 
Flt-3 Flt-3 Inhibitor 
Fms cFMS Receptor Tyrosine Kinase Inhibitor 
Fyn SU6656 
GSK GSK-3 inhibitor IX 
GSK 1-Azakenpaullone 
GSK indirubin-3'-monoxime 
HER2 AG825 
IGF-IR AG1024 
IGF-IR AGL 2263 
IKK BMS-345541 
IKK IKK-2 inhibitor VI 
IRAK IRAK-1/4 inhibitor 
Jak JAK Inhibitor I 
Jak JAK3 Inhibitor VI 
JNK SP600125 
JNK JNK inhibitor VIII 
Lck Damnacanthal 
Lck PP2 
MAPK ERK inhibitor II 
MEK PD98059 
MEK U-0126 
MEK MEK inhibitor I 
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 Met SU11274 
MLCK ML-7 
p38 SB202190 
p38 SB239063 
PDGFR AG1296 
PDGFR SU11652 
PDGFR PDGF receptor tyrosine kinase inhibitor V 
PDGFR PDGF receptor tyrosine kinase inhibitor IV 
PI3K LY-294002 
PI3K Wortmannin 
PKA H-89 
PKA 4-cyano-3-methylisoquinoline 
PKC Bisindolymaleimide I, HCl 
PKC Go7874 
PKG Rp-8-CPT-cGMPS 
PKG KT5823 
PKR PKR inhibitor 
Raf RAF1 kinase inhibitor I 
Raf ZM 336372 
ROCK H-1152 
ROCK Y-27632 
Hsp90 radicicol 
Src PP1 analog 
Syk Syk inhibitor 
TGF-βRI SB431542 
TGF-βRI TGF-b RI kinase inhibitor II 
Tpl2 Tpl2 kinase inhibitor 
TrKA TrkA inhibitor 
VEGFR VEGFR receptor tyrosine kinase inhibitor II 
VEGFR VEGF recptor 2 kinase inhibitor I 
VEGFR  SU1498 
Bcr-Abl nilotinib 
Multi-kinases sorafenib 
mTOR temsirolimus 
EGFR/Her2 lapatinib 
Bcr-Abl/Kit imatinib mesylate 
Multi-kinases sunitinib malate 
EGFR gefitinib 
HDAC vorinostat 
EGFR erlotinib 
Proteasome bortezomib 
Bcr-Abl/Src dasatinib 
mTOR everolimus 
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 Multi-kinases pazopanib 
Rho/SRF CCG-1423 
PIM PIM1/2 Kinase Inhibitor V  
PIM PIM1 Inhibitor II  
Hedgehog AY 9944  
Hedgehog cyclopamine 
Hedgehog Jervine 
STAT3 WP1066  
STAT3 5,15-DPP  
Wnt IWP-2 
Wnt IWR-1-endo 
Wnt FH535 
Notch DAPT 
tankyrase-selective PARP XAV939 
pan-PARP PJ-34 
PARP-1/2-selective Olaparib 
antipsychotic drug chlorpromazine hydrochloride 
depression treatment desipramine hydrochloride 
golgi inhibitor brefeldin A 
stress inducer anisomycin 
thalidomide family thalidomide 
thalidomide family lenalidomide 
retinoids tretinoin 
retinoids tamibarotene 
DNA alkylation temozolomide 
EML4-ALK crizotinib 
mTOR Torkinib 
lipase orlistat 
AR MDV3100 
caspase activator PAC-1 
blc-2 ABT-737 
G9a UNC0638 
G9a BIX01294 
LSD1 S2101 (LSD1 inhibitor II) 
PRMT1 AMI-1 
p300 C646 
SIRT1 SIRT1 inhibitor III 
SIRT1/2 Tenovin-6 
HDAC8 PCI-34051 
BRD4 bromodomain (+)-JQ1 
Telomerase TMPyP4 
PARP BSI-201 (Iniparib) 
PARP ABT-888 (Veliparib) 
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 PARP AG014699 (Rucaparib) 
PARP MK-4827 (Niraparib) 
Aurora ENMD-2076 
Aurora MLN8237 
Survivin YM155 
PDK1 OSU-03012 
IGF-IR OSI-906 
c-Met PF-04217903 
DNMT Decitabine 
Multi-kinases Vandetanib 
Multi-kinases Axitinib 
BRAF Vemurafenib 
JAK Ruxolitinib 
Hedgehog Vismodegib 
GLI1 Gant61 
FGFR PD173074 
ALK A83-01 
GSK-3 BIO 
GSK-3 TWS119 
GSK-3 CT99021 
TGFb-R LY2157299 
TGFb-R SD208 
ALK LDN193189 
ROCK Thiazovivin 
 
Table 1 SCADS screening. Totally 364 chemicals with 232 targets were examined in this screening.  
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Figure 3-20 SCADS screening. The most right inhibitor is YM155, which dereases STAT3 activity by > 
20 fold.  
 
 
Figure 3-21 AAG8-knockdown DLD-1 cells were treated with or without 100 nM YM155 for 12 h, 
followed by PBS or 10 ng/ml IL6 treatment for 1 h. Total lysates from control and stable knockdown cell 
lines were immunoblotted with pSTAT3 antibody; STAT3 served as loading control. 
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Figure 3-22 Immunoblot of pSTAT3 and STAT3 in DLD-1 cells treated with BD1047 or BD1063 for 12 h, 
followed by PBS or 10 ng/ml IL6 treatment for 1 h. Total lysates were immunoblotted with pSTAT3 
antibody; STAT3 served as loading control. 
 
 
 
Figure 3-23 Upper: AAG8-knockdown DLD-1 cells were treated with or without 1 μM Ruxolitinib for 20 
h, followed by PBS or 10 ng/ml IL6 treatment for 1 h. Juxtaposed lanes that were non-adjacent in the gel 
is indicated by a vertical black line. Lower: AAG8-knockdown DLD-1 cells were treated with or without 
100 nM JAK inhibitor I for 24 h, followed by PBS or 10 ng/ml IL6 treatment for 1 h. Total lysates from 
control and stable knockdown cells were immunoblotted with pSTAT3 antibody; STAT3 served as loading 
control. Mean values of pSTAT3 versus STAT3 levels in Ruxolitinib- or JAK inhibitor I-treated cells were 
labeled with shCtrl cells as standard. 
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 To interrogate the temporal regulation of STAT3 by YM155 in AAG8-knockdown cells, I decreased the 
time of YM155 treatment to 6 h or increased it to 18 h, respectively (Figure 3-24). YM155 treatment for 6 
h affected little to API4, however, AAG8 knockdown led to decreased STAT3 activity in YM155-treated 
cells. In contrast, YM155 treatment for 18 h led to decreased API4 expression, dramatically decreased 
STAT3 activity and even decreased total STAT3 level. Notably, AAG8 knockdown further abolished 
STAT3 activation and reduced API4 in YM155-treated cells. These data exclude the possibility that YM155 
inhibits STAT3 activation dependent on AAG8-related signallings. These results together give rise to the 
conclusion that AAG8 alternatively activates STAT3 in addition to IL6/JAK pathway. 
 
 
 
Figure 3-24 Temporal STAT3 regulation by YM155. Immunoblot of pSTAT3, STAT3 and API4 in AAG8-
knockdown DLD-1 cells treated with or without YM155 for the indicated time, followed by PBS or 10 
ng/ml IL6 treatment for 1 h. Total lysates were immunoblotted with pSTAT3, STAT3 and API4 antibodies; 
GAPDH served as loading control. 
 
API4 is an anti-apoptotic protein and its transcription can be concurrently modulated by several 
transcription factors such as STAT3 86, β-Catenin and YAP1 87. We could not establish the stable API4 
knockdown DLD-1 cell line, with the similar report elsewhere 88, due to its cytotoxicity. To investigate 
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 whether API4 is required for IL6-induced STAT3 activation, I transiently knocked down API4 in DLD-1 
cells with two specific shRNAs (Figure 3-25). To our surprise, API4 depletion was dispensable for IL6-
induced STAT3 phosphorylation in these cells (Figure 3-25). Although YM155 has been principally 
regarded as an API4 inhibitor, its specificity remains uncertain. As YM155 dramatically decreased IL6-
induced STAT3 activation while API4 knockdown did not, I supposed that YM155 might employ other 
inhibition mechanisms for this inactivation. There are at least two pieces of evidences supporting this 
argument: Firstly, in Figure 3-24, while YM155 treatment for 6 h did not decrease API4 expression, it had 
already cooperated with AAG8 knockdown to cooperatively decrease STAT3 activation; Secondly, YM155 
directly targets ILF3 (interleukin enhancer-binding factor 3), a transcription factor, to suppress API4 
expression 89. Apparently, some other proteins, in addition to API4, could also be suppressed by ILF3-
dependent YM155 treatment. In summary, YM155 appears to be a potent STAT3 inhibitor independent of 
its suppression on API4. 
 
 
Figure 3-25 Effect of API4 knockdown on IL6-induced STAT3 activation. Immunoblot of pSTAT3, 
STAT3 and API4 in transient API4-knockdown DLD-1 cells treated with PBS or 10 ng/ml IL6 treatment 
for 1 h. Total lysates were immunoblotted with pSTAT3, STAT3 and API4 antibodies; STAT3 served as 
loading control. 
 
Furthermore, though PKM2 (pyruvate kinase M2) was reported to translocate into nucleus and function 
as a direct kinase for STAT3 phosphorylation at Y705 90, I could not detect the changes in both expression 
level and cellular distribution of PKM2 upon AAG8 overexpression or knockdown (Figures 3-26, 3-27), 
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 suggesting that PKM2 might not be involved in AAG8-induced STAT3 activation. Taken together, our data 
identified AAG8 as an alternative STAT3 activator in addition to JAKs and PKM2 kinases.  
 
 
 
Figure 3-26 Immunoblot of PKM2 in DLD-1 cells with either AAG8 overexpression (left) or knockdown 
(right). Total lysates were immunoblotted with AAG8 antibody; GAPDH served as loading control. 
 
 
 
Figure 3-27 Immunoblot of PKM2 of total, cytoplasmic and nuclear fractions in AAG8-knockdown 
HCT116 cells. Lysates of indicated fractions were immunoblotted with PKM2 antibody. LMNB served as 
loading control for the nuclear fraction. GAPDH served as loading control for total and cytoplasmic 
fractions. 
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 3.4 Combined inhibition of AAG8 and JAK signalling 
 
I then supposed that combining YM155 and AAG8 knockdown could cooperatively suppress STAT3 
activation and cancer cell growth. Accordingly, I observed that YM155 treatment significantly limited 
DLD-1 cell growth in 3D culture, which was enhanced by AAG8 knockdown (Figure 3-28), suggesting the 
collaborative antitumor effects by the combined inhibition. Similarly, AAG8 knockdown significantly 
slowed the proliferation of DLD-1 cells treated with the JAK inhibitor JSI-124 (Figure 3-29) and JAK3 
Inhibitor VI (Figure 3-30), respectively.  
 
 
 
Figure 3-28 Phase contrast images showing acinar morphology of the indicated DLD-1 cells in 3D culture 
on day 5 after treatment with or without 100 nM YM155. 
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Figure 3-29 Growth assay of AAG8-knockdown DLD-1 cells treated with 1 μM JSI-124 (JAK inhibitor) 
for 24 h. Initial cell number = 6 × 105. n = 3. Error bars (s.e.m.) are indicated. *** p <0.001 (one way 
ANOVA followed by Tukey's test). 
 
 
 
Figure 3-30 Phase contrast images showing acinar morphology of the indicated DLD-1 cells in 3D culture 
on day 10 after treatment with or without 100 nM JAK3 inhibitor VI. 
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 4. Discussion 
 
In this study, I showed that AAG8, a chaperon protein, promotes carcinogenesis by activating STAT3. 
Inhibition of AAG8 by antagonists or shRNA efficiently suppressed cancer cell growth in vitro and tumor 
formation in vivo. Furthermore, from analysis using a drug screening, I pinpoint AAG8 as an alternative 
STAT3 activator in addition to IL6/JAK signalling. This study elucidates, for the first time, the critical roles 
of AAG8 in regulating JAK/STAT3 signalling pathway, though previous studies demonstrated that AAG8 
associated with several ion channels and/or receptors to regulate cellular ion signalling.34,35 
Although an AAG8 antagonist has been assessed for pain treatment in phase I studies 91, few have been 
tested for their anti-cancer property. I evaluated the anti-tumor effects of AAG8 antagonists, thus suggested 
the novel use of classical neurological drugs on cancer treatment. Some synthesized AAG8 ligands have 
been reported to specifically bind to AAG8 in the nanomolar range 15. Further efforts are needed to 
determine whether the anti-cancer ability of AAG8 antagonists could be translated in vivo. 
At present, the exact mechanisms by which AAG8 activates STAT3 is uncertain. STAT3 
phosphorylation on Y705 is concurrently and tightly controlled by multiple kinases and protein tyrosine 
phosphatases, which are a large and structurally diverse family of enzymes that catalyze the 
dephosphorylation. I demonstrated that STAT3 kinases are dispensable in AAG8-induced STAT3 
activation. However, there is possibility that dephosphorylation might account for AAG8-related regulation. 
For instance, PTPMeg2 is a physiologic STAT3 phosphatase that can directly dephosphorylate STAT3 at 
the Tyr705 residue 92. This possibility merits future detailed evaluation. 
Despite great efforts focusing on STAT3 for cancer therapy, few efficient strategies have been developed 
93. Single usage of chemical drugs targeting upstream kinases of STAT3, such as JAK2 inhibitors, often 
results in drug insensitivity due to acquired resistance 94. In the anticancer drugs screening, I identified 
YM155 as a potent STAT3 suppressant, suggesting that YM155 blocks the signalling activities which are 
absolutely required for IL6-induced STAT3 activation. I further illustrated that combined inhibition of 
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 AAG8 and IL6/JAK signalling more efficiently limits cancer cell growth. As single use of both JAK 
inhibitors and API4 inhibitor YM155 has clinical limitations 94,95, our drug combination strategy provides 
a promising therapeutic approach for increasing the antitumor efficacy and decreasing drug resistance.  
At least five lines of evidences have supported the notion that AAG8 antagonists have overwhelmingly 
higher specificity in cancer cells than in normal cells: 
 
Evidence 1: AAG8 knockout mouse. 
AAG8 knockout mice were created in 2009 and with this knockout mouse model, the hallucinogen 
N,N-Dimethyltryptamine (DMT) has been identified as an endogenous agonist of AAG8.96 Strangely, the 
mice demonstrated no overt phenotype. As expected, however, they did lack locomotor response to the 
AAG8 ligand (+)-SKF-10,047 and displayed reduced response to formalin-induced pain. These findings 
indicate that loss of AAG8 affects little on normal body cells except for the neurology system.  
 
Evidence 2: Clinical study of AAG8 antagonist. 
The safety, tolerability and pharmacokinetics of an AAG8 antagonist, S1RA, have been assessed in the 
clinical phase I studies for pain treatment. As a result, S1RA exhibited an acceptable safety, tolerability, 
pharmacodynamic and pharmacokinetic profile in healthy subjects over the dose range studied, though the 
most common side effects were headache and dizziness.91. These clinical data support the great potential 
of AAG8 antagonists as drugs for feasible application. 
 
Evidence 3: 100 μM BD1047 did not affect mouse hippocampal cells. 
Exogenously, a plethora of ligands of AAG8 have been synthesized.37,38 BD1047 and its analogue 
BD1063 are the two specific AAG8 antagonists which have been widely used to elaborate the functions of 
AAG8, especially in neuroscience. Consistent with the tiny changes of phenotype in AAG8 knockout mice, 
100 μM BD1047 (the routinely used concentration in vitro, I also used this concentration in my studies) 
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 treatment of mouse organotypic hippocampal slice cultures (normal cells) for 24 h did not affect cell growth 
(Figure 3-31).97  
 
 
Figure 3-31 Mouse organotypic hippocampal slice cultures treated with or without 100 μM BD1047 and 
cell viability was indicated by propidium iodide (PI) staining. (Smith, K. J. et al. Neuroscience letters, 2010) 
 
Evidence 4: 100 μM BD1047 did not affect human retinal cells. 
AAG8 stimulation is reported to protect against oxidative stress. AAG8 expression is markedly increased 
in response to H2O2 in human lens cells. Application of AAG8 agonist significantly inhibited the H2O2 
induced cell death and also suppressed the oxidative stress induced reduction of pro-caspase 12 and 
suppressed the induction of the ER stress proteins BiP and EIF2α. On the other hand, AAG8 agonist protects 
human lenses against apoptotic cell death, LDH release and against H2O2 induced opacification.37 In 
agreement with the nontoxicity to mouse organotypic hippocampal slice cellls,97 one study also showed that 
treatment with the same concentration of BD1047, as well as another AAG8 antagonist, NE-100, did not 
decrease the cell viability of human retinal pigment epithelial cells (Figure 3-32).98 As the figure indicates, 
BD1047 treatment even increased the percentage of cell viability, indicating the nontoxicity of AAG8 
antagonists on normal cells. 
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Figure 3-32 Effects of 100 μM BD1047 on death of ARPE-19 cells (human retinal pigment epithelium 
cells). (Bucolo, C. et al. Neuroreport, 2006) 
Evidence 5: AAG8 overexpression in cancer serves as the antagonist target. 
As AAG8 is overexpressed in the majority of cancer types, especially for melanoma. The upregulated 
AAG8 in cancer cells presents a preferential target for AAG8 antagonists. Accordingly, in all the cancer 
cells we tested (Table 2), AAG8 antagonists showed dramatic growth inhibitory effects on these cells. 
Importantly, all the results from gain- or loss-of-function studies, both in vitro and in vivo, are consistent. 
Our investigation of AAG8 in cancer cells, integrated with the published data, demonstrated that while 
AAG8 impacts little on normal body cells, it particularly play vital roles in carcinogenesis, Conclusively, 
specifically targeting AAG8 can be an efficient way for cancer therapy with minor side effects. 
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Table 2 Summary of the cancer cell lines and investigative methods used in this study. 
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 Chapter 4  Conclusion and Perspective 
 
Drug resistance presents a challenge to the treatment of cancer patients, especially for melanomas, most of 
which are caused by the hyperactivation of MAPK signaling pathway. Innate or acquired drug-resistant 
relapse calls for the investigation of the resistant mechanisms and new anti-cancer drugs to provide 
implications for the ultimate goal of curative therapy. This study discovered AAG8 antagonists as new 
MEK inhibitors in melanoma cells and propose a novel drug combination strategy by presenting the 
experimental evidences. Specific antagonism of AAG8, efficiently suppresses melanoma cell growth and 
migration through, at least in part, the inactivation of the RAS-CRAF-MEK signaling pathway. We further 
demonstrate that melanoma cells that are resistant to AAG8 antagonist harbor refractory CRAF-MEK 
activity. MEK acts as a central mediator for anti-cancer effects and also for the resistance mechanism, 
leading to my proposal of tandem AAG8-MEK inhibition in melanoma cells. Combination of AAG8 
antagonist and very low concentration of a MEK inhibitor cooperatively restricts the growth of drug-
resistant cells.  
In addition, the present study characterized AAG8 as an oncoprotein in multiple types of cancers through 
investigating its cancer-promoting effects and the underlying mechanisms. I uniquely uncovered the 
molecular clues that AAG8 is an alternative upstream STAT3 activator in addition to IL6/JAK signalling 
pathway. Tandem inhibition of AAG8 and JAK signalling cooperatively suppresses cancer cell growth. 
Taken together, these findings shed light on the fundamental evidences for identification of AAG8 as a 
potential target for cancer prevention, and highlight the importance of ER chaperon proteins in contributing 
to JAK/STAT signalling and carcinogenesis. 
Despite my characterization of AAG8 as an oncoprotein and the elucidation of the molecular mechanisms 
of AAG8 and it antagonists in cancer cells, how AAG8 directly regulates RAS and STAT3 activity has 
been currently unsolved. Further efforts should be made to seek the direct interacting partners of AAG8 or 
investigate the related involvement of AAG8 in some singalling cascades to clarify the activation 
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 mechanisms. It is also unclear whether AAG8-induced RAS activation and STAT3 activation could 
interplay with each other. Since proteins fulfill their functions by protein-protein interactions, generating 
an in vivo AAG8 interactome99 would be valuable for further explaining the mechanisms. The protein(s) 
that interact with AAG8 might serve as the common mediator(s) for the activation of the oncogenetic 
signalling pathways such as MAPK and JAK/STAT, and this would also explain the possible connections 
between AAG8-induced RAS activation and STAT3 activation. In such cases, AAG8 antagonists would 
disturb the interactions of AAG8 and its partners, and therefore inhibit AAG8 functions. 
In addition to AAG8, the sigma-2 receptor (σ2R) is a sigma receptor subtype which preferentially binds 
to siramesine. Unlike sigma-1 receptor, it has not yet been cloned. Since the AAG8 knockout mice show 
no obvious phenotypic change, this might be due to the genetic redundancy. However, knowledge of σ2R 
is extremely limited and the fundamental research of σ2R, such as cloning of this gene, should be addressed 
firstly to further test the hypothesis of genetic redundancy. 
Cellar distribution or translocation is another promising topic for illustrating the proper functions of 
proteins.100 Previous investigations have also points out the importance of the translocation of AAG8 
between ER membrane and cell membrane in the neurologic response.34 It has been well believed that 
AAG8 is a membrane-tethered protein that shuffles among the membrane structures in the cells, and this 
may provide a possible clue that AAG8 may interact with the membrane proteins, especially the receptor 
complexes on cell membrane, to impact on the oncogenetic signalling pathways. Supporting this, it was 
found that AAG8 directly bound to the Kv1.2 potassium channel on cell membrane to facilitate the K+ 
current.34 Future work should be aiming at the discovery of the constant or dynamic interactions between 
AAG8 and other membrane proteins or complexes. 
Moreover, since my studies imply that AAG8 might be a promising target for cancer therapy, especially 
in melanoma and colon cancer, and according drug combination strategies have been proposed based on 
the fundamental data, further in vivo and preclinical trials should be made to confirm their efficacy. 
Importantly, AAG8 antagonists with higher binding affinity and specificity should be designed and 
synthesized to decrease the using dosage and their side effects, these antagonists would become promising 
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 useful drugs in the combination with the current used clinical chemicals for cancer therapy and even other 
disease control.  
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